AB2231
Anti-Dopamine Transporter; 100 µg Antibody
from rabbit
Synonym(s):
DA transporter, dopamine transporter, solute carrier family 6 (neurotransmitter transporter, dopamine),member 3, variable number tandem repeat (VNTR)
Sign In to View Organizational & Contract Pricing
Select a Size
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
biological source
rabbit
Quality Level
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
species reactivity
mouse, rat
technique(s)
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
mouse ... Slc6A3(13162)
rat ... Slc6A3(24898)
General description
Plasmalemmal neurotransmitter transporters sequester synaptic and peri synaptic transmitter into presynaptic elements. The Dopamine Transporter (DAT), a 12 transmembrane domain transporter with the N and C terminal regions located within the cytoplasm is responsible for the reaccumulation of dopamine after it has been released. Levels of DAT protein expression are altered by chronic drug administration. The activity of the DAT reuptake carrier is sodium dependent, and it is suspected to play a role in such neurologic and psychiatric disorders as Parkinson′s disease, Tourette′s disease, schizophrenia, and addiction. DAT is also the target of several “DAT-blockers” including amphetamines and cocaine. These chemicals inhibit the action of DAT and, to a lesser extent, the other monoamine transporters, but their effects are mediated by separate mechanisms.
~ 50 – 80 kDa
Reduced form at approx 50 kDa and Non-reduced form at approx. 80 kDa
Reduced form at approx 50 kDa and Non-reduced form at approx. 80 kDa
Application
This Anti-Dopamine Transporter, 100 µg Antibody is validated for use in WB for the detection of Dopamine Transporter, 100 µg.
Biochem/physiol Actions
Cat. AB2231 recognizes the N-terminus of the reduced and non reduced forms of DAT.
Physical form
Format: Purified
Analysis Note
Routinelyevaluated by western blot on rat brain lysate.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Traumatic brain injury and trichloroethylene exposure interact and produce functional, histological, and mitochondrial deficits.
Sauerbeck, A; Hunter, R; Bing, G; Sullivan, PG
Experimental neurology null
Daniel W Curry et al.
Neuropharmacology, 128, 196-206 (2017-10-11)
S,R(+/-)-3,4-methylenedioxymethamphetamine (SR-MDMA) is an amphetamine derivative with prosocial and putative therapeutic effects. Ongoing clinical trials are investigating it as a treatment for post-traumatic stress disorder (PTSD) and other conditions. However, its potential for adverse effects such as hyperthermia and neurotoxicity
Dafina M Angelova et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 32(2), 995-1006 (2017-10-22)
α-Synuclein (α-syn) is associated with a range of diseases, including Parkinson disease. In disease, α-syn is known to aggregate and has the potential to be neurotoxic. The association between copper and α-syn results in the formation of stellate toxic oligomers
Gaia Faustini et al.
Neurobiology of disease, 138, 104789-104789 (2020-02-08)
Loss of dopaminergic nigrostriatal neurons and fibrillary α-synuclein (α-syn) aggregation in Lewy bodies (LB) characterize Parkinson's disease (PD). We recently found that Synapsin III (Syn III), a phosphoprotein regulating dopamine (DA) release with α-syn, is another key component of LB
Yuan-Yang Lai et al.
Movement disorders : official journal of the Movement Disorder Society, 32(12), 1687-1693 (2017-08-27)
Abnormal striatal dopamine transmission has been hypothesized to cause restless legs syndrome. Dopaminergic drugs are commonly used to treat restless legs syndrome. However, they cause adverse effects with long-term use. An animal model would allow the systematic testing of potential
Related Content
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service